Altered signaling in systemic juvenile idiopathic arthritis monocytes

Clinical Immunology

Volumn 163, Issue , 2016, Pages 66-74

  Macaubas, Claudia ^a   Wong, Elizabeth ^a   Zhang, Yujuan ^a,e   Nguyen, Khoa D ^a   Lee, Justin ^a   Milojevic, Diana ^b   Shenoi, Susan ^c   Stevens, Anne M ^c   Ilowite, Norman ^d   Saper, Vivian ^a   Lee, Tzielan ^a   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IFN signaling; Juvenile arthritis; Monocytes; SOCS1

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD16 ANTIGEN; GAMMA INTERFERON; JANUS KINASE; STAT1 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; INTERFERON; SOCS1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOGENESIS; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFANT; JUVENILE RHEUMATOID ARTHRITIS; METABOLISM; PHOSPHORYLATION; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ARTHRITIS, JUVENILE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INFANT; INTERFERON-GAMMA; INTERFERONS; MALE; MONOCYTES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

EID: 84953304113     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.12.011     Document Type: Article

References (52)

1. Mellins E., Macaubas C., Grom A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheumatol. 2011, 7:416-426.
2. Macaubas C., Nguyen K., Milojevic D., Park J., Mellins E. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat. Rev. Rheumatol. 2009, 5:616-626.
3. Barnes M.G., Grom A.A., Thompson S.D., Griffin T.A., Pavlidis P., Itert L., Fall N., Sowders D.P., Hinze C.H., Aronow B.J., Luyrink L.K., Srivastava S., Ilowite N.T., Gottlieb B.S., Olson J.C., Sherry D.D., Glass D.N., Colbert R.A. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60:2102-2112.
4. Ling X., Macaubas C., Alexander H., Wen Q., Chen E., Peng S., Sun Y., Deshpande C., Pan K.-H., Lin R., Lih C.-J., Chang S.-Y., Lee C., Sandborg C., Begovich A., Cohen S., Mellins E. Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis. BMC Med. 2012, 10:125.
5. Frosch M., Metze D., Foell D., Vogl T., Sorg C., Sunderkotter C., Roth J. Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp. Dermatol. 2005, 14:259-265.
6. Fall N., Barnes M., Thornton S., Luyrink L., Olson J., Ilowite N.T., Gottlieb B.S., Griffin T., Sherry D.D., Thompson S., Glass D.N., Colbert R.A., Grom A.A. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007, 56:3793-3804.
7. Macaubas C., Nguyen K., Peck A., Buckingham J., Deshpande C., Wong E., Alexander H., Chang S.-Y., Begovich A., Sun Y., Park J., Pan K.-H., Lin R., Lih C.-J., Augustine E., Phillips C., Hadjinicolaou A., Lee T., Mellins E. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin. Immunol. 2012, 142:362-372.
8. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005, 201:1479-1486.
9. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
10. de Jager W., Hoppenreijs E.P.A.H., Wulffraat N.M., Wedderburn L.R., Kuis W., Prakken B.J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 2007, 66:589-598.
11. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S., Delfino L., Ferlito F., Pelagatti M.A., Caroli F., Buoncompagni A., Viola S., Loy A., Sironi M., Vecchi A., Ravelli A., Martini A., Rubartelli A. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008, 58:1505-1515.
12. Lasiglie D., Traggiai E., Federici S., Alessio M., Buoncompagni A., Accogli A., Chiesa S., Penco F., Martini A., Gattorno M. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One 2011, 6. (e20014-e20014).
13. Omoyinmi E., Hamaoui R., Pesenacker A., Nistala K., Moncrieffe H., Ursu S., Wedderburn L.R., Woo P. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology 2012, 51:1881-1886.
14. Ogilvie E.M., Khan A., Hubank M., Kellam P., Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007, 56:1954-1965.
15. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., Bossuyt X., Boutten A., Bienvenu J., Duquesne A., Richer O., Chaussabel D., Mogenet A., Banchereau J., Treluyer J.-M., Landais P., Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 2011, 70:747-754.
16. Ishikawa S., Mima T., Aoki C., Yoshio-Hoshino N., Adachi Y., Imagawa T., Mori M., Tomiita M., Iwata N., Murata T., Miyoshi M., Takei S., Aihara Y., Yokota S., Matsubara K., Nishimoto N. Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann. Rheum. Dis. 2009, 68:264-272.
17. Bacon T.H., de Vere-Tyndall A., Tyrrell D.A., Denman A.M., Ansell B.M. Interferon system in patients with systemic juvenile chronic arthritis: in vivo and in vitro studies. Clin. Exp. Immunol. 1983, 54:23-30.
18. de Vere-Tyndall A., Bacon T., Parry R., Tyrrell D.A., Denman A.M., Ansell B.M. Infection and interferon production in systemic juvenile chronic arthritis: a prospective study. Ann. Rheum. Dis. 1984, 43:1-7.
19. Perez O., Nolan G. Phospho-proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single-cell level. Immunol. Rev. 2006, 210:208-228.
20. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A.-M., Suarez-Almazor M.E., Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004, 31:390-392.
21. Macaubas C., Nguyen K., Deshpande C., Phillips C., Peck A., Lee T., Park J., Sandborg C., Mellins E. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin. Immunol. 2010, 134:206-216.
22. Sandborg C., Holmes T.H., Lee T., Biederman K., Bloch D.A., Emery H., McCurdy D., Mellins E.D. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol. 2006, 33:2322-2329.
23. Lee A.W., Sharp E.R., O'Mahony A., Rosenberg M.G., Israelski D.M., Nolan G.P., Nixon D.F. Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J. Virol. 2008, 82:3702-3712.
24. Hornell T.M.C., Beresford G.W., Bushey A., Boss J.M., Mellins E.D. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J. Immunol. 2003, 171:2374-2383.
25. Goentoro L., Kirschner M.W. Evidence that fold-change, and not absolute level, of β-catenin dictates Wnt signaling. Mol. Cell 2009, 36:872-884.
26. Cohen-Saidon C., Cohen A.A., Sigal A., Liron Y., Alon U. Dynamics and variability of ERK2 response to EGF in individual living cells. Mol. Cell 2009, 36:885-893.
27. Bhattacharyya S., Zhao Y., Kay T.W., Muglia L.J. Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate toll-like receptor-induced STAT1 activation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9554-9559.
28. Dorman S.E., Holland S.M. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 1998, 101:2364-2369.
29. Ilowite N.T., Prather K., Lokhnygina Y., Schanberg L.E., Elder M., Milojevic D., Verbsky J.W., Spalding S.J., Kimura Y., Imundo L.F., Punaro M.G., Sherry D.D., Tarvin S.E., Zemel L.S., Birmingham J.D., Gottlieb B.S., Miller M.L., O'Neil K., Ruth N.M., Wallace C.A., Singer N.G., Sandborg C.I. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. (Hoboken, N.J.) 2014, 66:2570-2579.
30. Avau A., Mitera T., Put S., Put K., Brisse E., Filtjens J., Uyttenhove C., Van Snick J., Liston A., Leclercq G., Billiau A., Wouters C., Matthys P. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-gamma. Arthritis Rheum. 2014, 66:1340-1351.
31. Porta C., Rimoldi M., Raes G., Brys L., Ghezzi P., Di Liberto D., Dieli F., Ghisletti S., Natoli G., De Baetselier P., Mantovani A., Sica A. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14978-14983.
32. Parsa K.V.L., Butchar J., Rajaram M.V.S., Cremer T., Gunn J., Schlesinger L., Tridandapani S. Francisella gains a survival advantage within mononuclear phagocytes by suppressing the host IFNgamma response. Mol. Immunol. 2008, 45:3428-3437.
33. Gordon S., Martinez F. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
34. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., Corbin J.E., Cornish A.L., Darwiche R., Owczarek C.M., Kay T.W., Nicola N.A., Hertzog P.J., Metcalf D., Hilton D.J. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
35. Gavrilescu L.C., Butcher B.A., Del Rio L., Taylor G.A., Denkers E.Y. STAT1 is essential for antimicrobial effector function but dispensable for gamma interferon production during Toxoplasma gondii infection. Infect. Immun. 2004, 72:1257-1264.
36. Whyte C.S., Bishop E.T., Rückerl D., Gaspar-Pereira S., Barker R.N., Allen J.E., Rees A.J., Wilson H.M. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J. Leukoc. Biol. 2011, 90:845-854.
37. Liu Y., Stewart K.N., Bishop E., Marek C.J., Kluth D.C., Rees A.J., Wilson H.M. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J. Immunol. 2008, 180:6270-6278.
38. Hale M., Krutzik P., Samra S., Crane J., Nolan G. Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus. PLoS One 2009, 4:e6756.
39. Oh J., Hur M.W., Lee C.E. SOCS1 protects protein tyrosine phosphatases by thioredoxin upregulation and attenuates Jaks to suppress ROS-mediated apoptosis. Oncogene 2009, 28:3145-3156.
40. Srivastava S., Macaubas C., Deshpande C., Alexander H., Chang S.-Y., Sun Y., Park J., Lee T., Begovich A., Mellins E. Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin. Immunol. 2010, 136:257-268.
41. Strengell M., Lehtonen A., Matikainen S., Julkunen I. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J. Leukoc. Biol. 2006, 79:1279-1285.
42. Wei L., Laurence A., Elias K.M., O'Shea J.J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 2007, 282:34605-34610.
43. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1[beta] and 6 but not transforming growth factor-[beta] are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007, 8:942-949.
44. Tanaka K., Ichiyama K., Hashimoto M., Yoshida H., Takimoto T., Takaesu G., Torisu T., Hanada T., Yasukawa H., Fukuyama S., Inoue H., Nakanishi Y., Kobayashi T., Yoshimura A. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-γ on STAT3 and Smads. J. Immunol. 2008, 180:3746-3756.
45. Sikora K., Fall N., Thornton S., Grom A. The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. Arthritis Rheum. 2012, 64:3799-3808.
46. De Jager W., Vastert S., Noordman B., Holzinger D., Kuis W., Prakken B., Wulffraat N. Anakinra restores the defective IL-18 NK cell axis in steroid naive systemic onset JIA patients. Ann. Rheum. Dis. 2011, 70:89.
47. Diehl S., Anguita J., Hoffmeyer A., Zapton T., Ihle J.N., Fikrig E., Rincon M. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 2000, 13:805-815.
48. Choi Y.S., Park J.K., Kang E.H., Lee Y.K., Kim T.K., Chung J.H., Zimmerer J.M., Carson W.E., Song Y.W., Lee Y.J. Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. Arthritis Res. Ther. 2013, 15:R191.
49. Guarda G., Braun M., Staehli F., Tardivel A., Mattmann C., Forster I., Farlik M., Decker T., Pasquier R.A.D., Romero P., Tschopp J. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223.
50. Mishra B.B., Rathinam V.A., Martens G.W., Martinot A.J., Kornfeld H., Fitzgerald K.A., Sassetti C.M. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat. Immunol. 2013, 14:52-60.
51. Hu X., Ho H.H., Lou O., Hidaka C., Ivashkiv L.B. Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. J. Immunol. 2005, 175:131-138.
52. Page C., Smale S., Carty S., Amos N., Lauder S., Goodfellow R., Richards P., Jones S., Topley N., Williams A. Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Res. Ther. 2010, 12:R49.